Journal
Molecular Cancer Therapeutics
Publication Date
10-1-2024
Volume
23
Issue
10
First Page
1494
Last Page
1510
Document Type
Open Access Publication
DOI
10.1158/1535-7163.MCT-23-0564
Rights and Permissions
Chen A, Kim BJ, Mitra A, Vollert CT, Lei JT, Fandino D, Anurag M, Holt MV, Gou X, Pilcher JB, Goetz MP, Northfelt DW, Hilsenbeck SG, Marshall CG, Hyer ML, Papp R, Yin SY, De Angelis C, Schiff R, Fuqua SAW, Ma CX, Foulds CE, Ellis MJ. PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 Oct 1;23(10):1494-1510. doi: 10.1158/1535-7163.MCT-23-0564 This open access article is distributed under the Creative Commons Attribution NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. ©2024 The Authors; Published by the American Association for Cancer Research
Recommended Citation
Chen, Anran; Ma, Cynthia X; and et al., "PKMYT1 is a marker of treatment response and a therapeutic target for CDK4/6 inhibitor-resistance in ER+ breast cancer." Molecular Cancer Therapeutics. 23, 10. 1494 - 1510. (2024).
https://digitalcommons.wustl.edu/oa_4/4200
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
